Drug intelligence / Profile preview

86Y-CHX-A″-DTPA-cetuximab

Development stage: Preclinical
Lead developer: National Cancer Institute
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**86Y-CHX-A″-DTPA-cetuximab** is an investigational EGFR-targeted PET radioimmunoconjugate. It consists of the chimeric anti-EGFR monoclonal antibody cetuximab covalently linked to the bifunctional chelator CHX-A″-DTPA and labeled with positron-emitting yttrium-86. The agent binds epidermal growth factor receptor-expressing tumors and was evaluated preclinically for quantitative PET imaging of colorectal, ovarian, pancreatic, and prostate cancer xenografts. Its yttrium-86 distribution is also intended to provide a PET imaging surrogate for potential yttrium-90 radioimmunotherapy using an analogous construct.

Other names: (86)Y-CHX-A''-DTPA-cetuximab86Y-CHX-A''-DTPA-cetuximab86Y-CHX-A′′-DTPA-cetuximab

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on 86Y-CHX-A″-DTPA-cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 86Y-CHX-A″-DTPA-cetuximab.

Explore the full profile